Patent · US Active

Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors

US7863312B2 · kind B2 · utility

1Cited by

5References

17Claims

0Family size

Assignee

MERCK SERONO SA · CH

Inventors

Gian Luca Araldi · Plymouth, US
Yihua Liao · Westwood, US
Adulla P. Reddy · Walpole, US
Zhong Zhao · Munich, DE

Key dates

Filing date	May 14, 2008
Grant date	Jan 4, 2011
Priority date	—
Expiry date	May 14, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D231/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteoporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin EP2 and/or EP4 receptors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.